Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrew McConaghie

Senior Writer

Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.

He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.

Latest From Andrew McConaghie

CureVac Could Be Third mRNA Vaccine Approval – But With A ‘Europe First’ Approach

Caught in a ‘vaccine nationalism’ crossfire a year ago, CureVac is now well placed to become a commercial entity – just as long as its mRNA platform can deliver.

BioPharmaceutical Commercial

After J&J Vaccine Pause, Urgent Safety Questions for Sputnik And CanSino On Possible ‘Class Effect’

Potentially fatal blood clots seen in AZ and J&J’s COVID-19 vaccine could be common to all adenovirus vector vaccines – but Russia and China developers are dismissing a possible link.

Safety Vaccines

After J&J Vaccine Pause, Urgent Safety Questions for Sputnik And CanSino

Potentially fatal blood clots seen in AZ and J&J’s COVID-19 vaccine could be common to all adenovirus vector vaccines – but Russia and China developers are dismissing a possible link.

BioPharmaceutical Companies

Vaccitech Prepares For IPO, But AZ COVID-19 Vaccine Safety Fears Cloud Launch

The UK biotech aims to raise $100m, but will need to tackle safety concerns to secure a long-term future.

Companies Commercial

Sanofi Adds mRNA Specialist Tidal To Acquisition Spree

Sanofi has paid out $160m to add to its in-house expertise in mRNA and novel cell therapy technologies.

Commercial Companies

AZ’s ‘Long Shot’ COVID-19 Trial Of Diabetes Drug Farxiga Fails

The failure of the SGLT2 inhibitor is not unexpected, but allays any concerns that it could have worsened outcomes for patients with hypertension or heart disease.

Companies Commercial
See All
UsernamePublicRestriction

Register